Lipocine (NASDAQ:LPCN) Now Covered by StockNews.com

Investment analysts at StockNews.com started coverage on shares of Lipocine (NASDAQ:LPCN) in a report released on Friday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Lipocine Stock Up 2.3 %

LPCN opened at $5.44 on Friday. The firm has a market cap of $28.94 million, a PE ratio of -1.78 and a beta of 1.05. The business has a fifty day simple moving average of $4.45 and a 200-day simple moving average of $3.46. Lipocine has a fifty-two week low of $2.31 and a fifty-two week high of $7.15.

Lipocine (NASDAQ:LPCN) last announced its earnings results on Thursday, March 7th. The specialty pharmaceutical company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.11. The company had revenue of $0.22 million for the quarter. On average, equities research analysts anticipate that Lipocine will post -1.49 EPS for the current fiscal year.

Institutional Investors Weigh In On Lipocine

A number of large investors have recently made changes to their positions in LPCN. BlackRock Inc. boosted its stake in Lipocine by 0.4% in the 1st quarter. BlackRock Inc. now owns 1,467,420 shares of the specialty pharmaceutical company’s stock worth $467,000 after purchasing an additional 6,348 shares during the period. Renaissance Technologies LLC grew its holdings in shares of Lipocine by 146.2% during the third quarter. Renaissance Technologies LLC now owns 199,400 shares of the specialty pharmaceutical company’s stock valued at $90,000 after buying an additional 118,394 shares in the last quarter. Millennium Management LLC acquired a new position in Lipocine during the second quarter valued at $160,000. Goldman Sachs Group Inc. raised its position in Lipocine by 524.6% during the first quarter. Goldman Sachs Group Inc. now owns 88,615 shares of the specialty pharmaceutical company’s stock valued at $121,000 after buying an additional 74,428 shares during the period. Finally, State Street Corp lifted its stake in Lipocine by 7.5% in the 1st quarter. State Street Corp now owns 327,405 shares of the specialty pharmaceutical company’s stock worth $449,000 after acquiring an additional 22,788 shares in the last quarter. Institutional investors and hedge funds own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.